[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai
Kensei
K
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D046988:Proteasome Endopeptidase Complex / Q000502:physiology; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex